Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
12/2012
12/13/2012US20120315282 Antibodies Specific for TGF-Beta
12/13/2012US20120315279 Compositions and method of modulating growth factor function
12/13/2012US20120315266 Detecting complement activation
12/13/2012US20120315265 Hydrogel-forming polymer, and preparation process and uses thereof
12/13/2012US20120315256 Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
12/13/2012DE112009004409T5 Verfahren zur Hornhautchirurgie A method for corneal surgery
12/13/2012CA2838818A1 Methods of treatment for retinal diseases
12/12/2012EP2532390A2 Pharmaceutical composition for obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
12/12/2012EP2532389A2 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
12/12/2012EP2532388A2 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
12/12/2012EP2532357A2 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
12/12/2012EP2531508A1 Pyrrolo [ 2, 3 - d]pyrimidine urea compounds as jak inhibitors
12/12/2012EP2531222A1 Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
12/12/2012EP2531184A1 Docosahexaenoic acid ethyl esters and/or its derivatives for prevention and/or treatment of age-related macular degeneration
12/12/2012CN102822188A Adenosine compounds and their use thereof
12/12/2012CN102822177A Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
12/12/2012CN102821773A Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient
12/12/2012CN102816090A Carbamate compounds, preparation method and application thereof
12/12/2012CN102813923A Combination Therapy for the Treatment of Ocular Neovascular Disorders
12/12/2012CN102813899A Medicament for treating intractable vertigo
12/12/2012CN102813796A Heat-clearing and dampness-removing tablets
12/12/2012CN102813780A Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof
12/12/2012CN102813761A Fire-purging and heat-clearing tablets
12/12/2012CN102813753A Composition containing Cistanche deserticola or Herba Cynomorii and combination of chrysanthemum, taurine, lycopene, xanthophyll and beta-carotene
12/12/2012CN102813735A Eruption-promoting and toxin-removing tablets
12/12/2012CN102813666A Application of notoginsenoside R1 in medicine for preventing and treating neurologic and ophthalmic diseases
12/12/2012CN102048747B Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof
12/12/2012CN101801941B Pharmaceutical containing ppar delta agonist
12/12/2012CN101480385B Use of methionine
12/11/2012US8329742 Macrocyclic compounds useful as pharmaceuticals
12/11/2012US8329673 Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof
12/11/2012US8329662 Prodrug of an ICE inhibitor
12/11/2012US8329190 Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
12/11/2012CA2620374C Pharmaceutical compositions for the treatment of inner ear disorders
12/06/2012WO2012166610A1 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
12/06/2012WO2012166287A1 Method of treating vision disorders
12/06/2012WO2012165398A1 Cycloalkyloxybiaryl compound
12/06/2012WO2012165314A1 Amide compound
12/06/2012WO2012163827A2 Ophthalmic preparation comprising a pgf2alpha analogue
12/06/2012WO2012134187A3 Pharmaceutical composition for preventing or treating macular degeneration
12/06/2012US20120310144 Vision through photodynamic therapy of the eye
12/06/2012US20120310141 Light delivery device and related compositions, methods and systems
12/06/2012US20120309836 Methods and compositions for administration of trpv1 agonists
12/06/2012US20120309835 Methods, assays and compositions for treating retinol-related diseases
12/06/2012US20120309833 Novel bexarotene analogs
12/06/2012US20120309814 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
12/06/2012US20120309804 Compositions and methods for treatment of glaucoma
12/06/2012US20120309791 Novel compound for the treatment of diseases associated with amyloid or amyloid-like proteins
12/06/2012US20120309782 THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS
12/06/2012US20120309776 Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors
12/06/2012US20120309761 Fast-response photochromic nanostructured contact lenses
12/06/2012US20120309759 Screening Method and Compounds for Modulating Telomerase Activity
12/06/2012US20120309758 Modulators of atp-binding cassette transporters
12/06/2012US20120309720 Compositions and methods for treatment of glaucoma
12/06/2012US20120308645 Compositions and methods for sirna inhibition of hif-1 alpha
12/06/2012US20120308644 Compositions for mucosal delivery of agents
12/06/2012US20120308588 Neprilysin inhibitors
12/06/2012US20120308573 Anti-IL-23 Antibodies, Compositions, Methods and Uses
12/06/2012US20120308518 Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
12/06/2012US20120308483 Treatment of Sleep Disturbances
12/06/2012CA2837240A1 Ophthalmic preparation comprising a pgf2.alpha. analogue
12/06/2012CA2836946A1 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
12/06/2012CA2834373A1 Method of treating vision disorders
12/05/2012EP2528908A1 Therapeutic agents for treatment of ocular hypertension
12/05/2012EP2528907A1 Therapeutically active cyclopentanes
12/05/2012CN102812005A Inhibitors of beta-secretase
12/05/2012CN102811745A Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
12/05/2012CN102807617A Antibodies to M-CSF
12/05/2012CN102805865A Eye drop administration device system and preparation
12/05/2012CN102274202B Daidzein nanocrystal immediate-release capsule and preparation process thereof
12/05/2012CN102210672B Application of polyketide in preparation of angiogenesis inhibiting medicine
12/05/2012CN102056609B Pharmaceutical combination
12/05/2012CN101951899B Abnormal intraocular pressure treatment
12/05/2012CN101835473B Novel ophthalmic compositions containing latanoprost
12/05/2012CN101784285B Composition for ophthalmic disease associated with hypoxia or ischemia
12/05/2012CN101553235B Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
12/04/2012US8324224 A2B adenosine receptor antagonists
12/04/2012CA2582934C Composition containing omega-3 fatty acids and omega-6 fatty acids
12/04/2012CA2573479C Effective use method of medicaments and method of preventing expression of side effect
12/04/2012CA2567418C Viscous agent for ophthalmic use
12/04/2012CA2521177C Use of a botulinum neurotoxin to alleviate various disorders
12/04/2012CA2474798C Method and composition for treatment of inflammation and aids-associated neurological disorders
12/04/2012CA2443345C Disease-associated protein
12/04/2012CA2222509C Connective tissue growth factor
11/2012
11/29/2012WO2012162627A1 Treatment of angiogenic- or vascular-associated diseases
11/29/2012WO2012162257A2 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
11/29/2012WO2012161877A1 Pyridine-and pyrazine derivatives
11/29/2012WO2012161655A1 Composition and/or method for reducing and/or preventing myopia progression comprising atropine
11/29/2012WO2012161173A1 Substituted amide compound
11/29/2012WO2012161112A1 Novel metalloprotein and process for producing same, and prophylactic or therapeutic agent for corneal and conjunctival diseases comprising said metalloprotein
11/29/2012WO2012160187A1 Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
11/29/2012WO2012160186A1 Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
11/29/2012WO2012159569A1 Application for prdx2 and/or prdx6 in preparation of pharmaceutical composition to treat or prevent damage, aging or disease resulting from increase of reactive oxygen species
11/29/2012WO2012159548A1 Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
11/29/2012US20120302621 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
11/29/2012US20120302620 Novel pyrone-indole derivatives and process for their preparation
11/29/2012US20120302607 C4-substituted alpha-keto oxazoles
11/29/2012US20120302602 Vanilloid Receptor Ligand Compounds, Pharmaceutical Compositions Containing Them, a Method of Producing Them and the Use Thereof to Treat Pain and Various Other Conditions
11/29/2012US20120302601 Compositions and methods for the treatment of macular degeneration
11/29/2012US20120302599 KAT ll INHIBITORS
1 ... 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 ... 531